A Multicenter, Post-Market Observational (non-interventional) Study of SUPARTZ in Subjects with Osteoarthritis of the Knee or Periarthritis of the Shoulder

A Multicenter, Post-Market Observational (non-interventional) Study of SUPARTZ in Subjects with Osteoarthritis of the Knee or Periarthritis of the Shoulder - Post-Market Observational Study of SUPARTZ

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038272

Enrollment

Registered

2019-10-21

Start date

2020-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the Knee or Periarthritis of the Shoulder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects who provide their written informed consent. 2. Subject who has a diagnosis of OA of the knee or periarthritis of the shoulder at the time of before first injection. The definition of OA of the knee is reference to the following American College of Rheumatology (ACR) criteria.

Exclusion criteria

Exclusion criteria: 1. Subjects for whom the product is contraindicated according to the Instructions For Use or subjects to whom, in any case, the product is administered not in accordance with the Instructions For Use. 2. Subjects with a history of hypersensitivity due to any ingredients of SUPARTZ.

Design outcomes

Primary

Measure	Time frame
Safety - Occurrence of adverse events and adverse reactions	—

Secondary

Measure	Time frame
Efficacy - Changes from baseline of pain in osteoarthritis (OA) of the knee and periarthritis of the shoulder	—

Countries

Europe

Contacts

Public ContactTadamasa Kobayashi

SEIKAGAKU CORPORATION Pharmacovigilance Dept.

ce_pms@seikagaku.co.jp03-5220-8556

Outcome results